Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Depreciation & Amortization (CF) (2021 - 2025)

Historic Depreciation & Amortization (CF) for Kezar Life Sciences (KZR) over the last 5 years, with Q3 2025 value amounting to $227000.0.

  • Kezar Life Sciences' Depreciation & Amortization (CF) fell 1269.23% to $227000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $980000.0, marking a year-over-year decrease of 763.43%. This contributed to the annual value of $1.0 million for FY2024, which is 243.9% down from last year.
  • Kezar Life Sciences' Depreciation & Amortization (CF) amounted to $227000.0 in Q3 2025, which was down 1269.23% from $243000.0 recorded in Q2 2025.
  • Kezar Life Sciences' 5-year Depreciation & Amortization (CF) high stood at $458000.0 for Q3 2022, and its period low was -$283000.0 during Q4 2022.
  • For the 5-year period, Kezar Life Sciences' Depreciation & Amortization (CF) averaged around $282105.3, with its median value being $261000.0 (2024).
  • In the last 5 years, Kezar Life Sciences' Depreciation & Amortization (CF) plummeted by 17312.66% in 2022 and then skyrocketed by 19893.99% in 2023.
  • Quarter analysis of 5 years shows Kezar Life Sciences' Depreciation & Amortization (CF) stood at $387000.0 in 2021, then tumbled by 173.13% to -$283000.0 in 2022, then soared by 198.94% to $280000.0 in 2023, then fell by 7.5% to $259000.0 in 2024, then dropped by 12.36% to $227000.0 in 2025.
  • Its Depreciation & Amortization (CF) was $227000.0 in Q3 2025, compared to $243000.0 in Q2 2025 and $251000.0 in Q1 2025.